Jan 21, 2014 – Medimmune Ongoing
ANCHOR LEAD: IN CONTRAST TO MANY INDUSTRY RELATIONSHIPS, JOHNS HOPKINS IS PLANNING A LONG TERM RELATIONSHIP WITH MEDIMMUNE, ELIZABETH TRACEY REPORTS
Many relationships between academic institutions and industry are project-based, but not so a new endeavor between MedImmune, a biotech concern, and Johns Hopkins. Landon King, executive vice dean of Johns Hopkins Medicine, says the areas of overlap are many.
KING: We have complimentary interests in a number of areas, including cancer, infectious disease, autoimmune diseases to name a few, and so there were opportunities that were created across a number of areas simultaneously. In addition though we’re talking together about how to create new opportunities for postdoctoral training, training opportunities are MedImmune, exchange of scientists between our campus and theirs for educational seminars, scientific symposia, or other types of opportunities where we think that we can come together in improving health. :32
King says funding issues have accelerated such joint enterprises for many, and feels confident they can be beneficial for all concerned. At Johns Hopkins, I’m Elizabeth Tracey.